OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 64 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Follow-Up Questions
What is the price performance of ORPOF stock?
The current price of ORPOF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for OSE Immunotherapeutics SA?
OSE Immunotherapeutics SA belongs to Biotechnology industry and the sector is Health Care
What is OSE Immunotherapeutics SA market cap?
OSE Immunotherapeutics SA's current market cap is $NaN
Is OSE Immunotherapeutics SA a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for OSE Immunotherapeutics SA, including 1 strong buy, 6 buy, 1 hold, 0 sell, and 1 strong sell